Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany

European Journal of Health Economics

Volumn 7, Issue 4, 2006, Pages 290-296

  Greiner, W ^a   Lehmann, K ^b   Earnshaw, S ^c   Bug, C ^d   Sabatowski, R ^b  

^a BIELEFELD UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c RTI HEALTH SOLUTIONS   (United States)

^d JANSSEN CILAG GMBH   (Germany)

Author keywords

Buprenorphine; Chronic pain; Fentanyl; Morphine; Oxycodone

Indexed keywords

BUPRENORPHINE; FENTANYL; MORPHINE; OXYCODONE;

ARTICLE; CHRONIC PAIN; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; REFERENCE DATABASE; SENSITIVITY ANALYSIS;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; FENTANYL; GERMANY; HEALTH SERVICES; HUMANS; MORPHINE; OXYCODONE; PAIN; QUALITY-ADJUSTED LIFE YEARS;

EID: 33847302579     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0376-8     Document Type: Article

References (37)

1. Ackerman SJ, Mordin M, Reblando J et al. (2003) Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 9: 223-231
2. Allan L, Hays H, Jensen NH et al. (2001) Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322: 1154-1158
3. Anonymous (2004) Rote Liste: Arzneimittelverzeichnis für Deutschland. Available at: http://www.roteliste.de
4. Barbieri M, Drummond M, Willke R et al. (2005) Variability of cost-effectiveness estimates for pharmaceuticals in western Europe: lessons for inferring generalizability. Value Health 8: 10-23
5. Bejvancicky S (2004) Efficacy and cost-effectiveness of chronic pain therapy with TTS fentanyl and TDS buprenorphine in Czechia: a comparative evaluation. Poster presented at WIP, Barcelona
6. Böger RH, Schmidt G (2004) Analgetika. In: Schwabe U, Paffrath D (eds) Arneiverordnungsreport 2004. Springer, Berlin Heidelberg New York, pp 207-221
7. Caldwell JR, Hale ME, Boyd RE et al. (1999) Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 26:862-869
8. Caldwell JR, Rapoport RJ, Davis JC et al. (2002) Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 23: 278-291
9. Christie AH, Culbert P, Guest JF (2002) Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics 20: 49-60
10. Clark AJ, Ahmedzai SH, Allan LG et al. (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20: 1419-1428
11. Detsky AS, McLaughlin JR, Abrams HB et al. (1986) A cost-utility analysis of the home parenteral nutrition program at Toronto General Hospital: 1970-1982. JPEN J Parenter Enteral Nutr 10: 49-57
12. Frei A, Andersen S, Hole P, Jensen NH (2003) A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother 17:5-26
13. Fryback DG, Lawrence WF, Martin PA et al. (1997) Predicting quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 17: 1-9
14. Goossens MEJB, Vlaeyen JWS, Rutten-van Molken MPMH, van der Linden SMJP (1999) Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method? Pain 80: 365-375
15. Guest JF, Hart WM, Cookson RF (1998) Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Pharmacoeconomics 14: 285-297
16. Haentjens P, De Groote K, Annemans L (2004) Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg 124: 507-517
17. Hale ME, Fleischmann R, Salzman R et al. (1999) Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 15: 179-183
18. James M, Leger S, Rowsell KV (1996) A cost-utility analysis of orthopaedics in the northwest of England. J Epidemiol Community Health 50: 182-189
19. Kalso E, Allan L, Dellemijn PL et al. (2003) Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 7: 381-386
20. Lehmann K, Radbruch L, Gockel HH et al. (2002) Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur J Health Econ 3: 111-119
21. Maier C, Tölle TR, Sabatowski R et al. (2002) Langzeitanwendung von Opioiden bei nichttumorbedingten Schmerzen. Dtsch Arztebl 99: A-2180
22. Malter AD, Larson EB, Urban N, Deyo RA (1996) Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. Spine 21: 1048-1054
23. Milligan K, Lanteri-Minet M, Borchert K et al. (2001) Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2: 197-204
24. Neighbors DM, Bell TJ, Wilson J, Dodd SL (2001) Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage 21: 129-143
25. Nicholson B (2003) Responsible prescribing of opioids for the management of chronic pain. Drugs 63: 17-32
26. Nink K, Schröder H (2004) Ergänzende statistische Übersicht. In: Schwabe U, Paffrath D (eds) Arzneiverordnungsreport 2004. Springer, Berlin Heidelberg New York, pp 1115-1212
27. Radbruch L, Sabatowski R, Loick G et al. (2000) Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14: 111-119
28. Roth SH, Fleischmann RM, Burch FX et al. (2000) Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 160: 853-860
29. Salzman RT, Roberts MS, Wild J et al. (1999) Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 18: 271-279
30. Schmier JK, Palmer CS, Flood EM, Gourlay G (2002) Utility assessments of opioid treatment for chronic pain. Pain Med 3: 218-230
31. Schulenburg JM, Greiner W (2002) Gesundheitsökonomik. Mohr Siebeck, Tübingen
32. Smith C, Crowther C, Beilby J, Dandeaux J (2000) The impact of nausea and vomiting on women: a burden of early pregnancy. Aust N Z J Obstet Gynaecol 40: 397-401
33. Wallenhammar LM, Nyfjall M, Lindberg M, Meding B (2004) Health-related quality of life and hand eczema-a comparison of two instruments, including factor analysis. J Invest Dermatol 122: 1381-1389
34. Watson CP, Babul N (1998) Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50: 1837-1841
35. World Health Organization (1990) Cancer pain relief and palliative care: report of a WHO expert committee. Technical report series 804. World Health Organization, Geneva, Switzerland
36. World Health Organization (1996) Cancer pain relief, 2nd edn.. World Health Organization, Geneva
37. World Health Organization (2004) Cancer pain relief and palliative care: report of a WHO expert committee. World Health Organization, Geneva